RxDoctor Payments Data

Robert Lehr, MD

Dermatology · Oklahoma City, OKNPI 1619901634

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 542 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,754, 4.3 times the $635 reported in 2019.

$10,754in general payments, 2019–2025

Across 542 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$987
  • Johnson & Johnson$887
  • plus $4K from 22 others

What the payments were for

  • Food & beverage$10,29596%
  • Education$4594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,754 in reported general payments places this provider in the 80th percentile of 114 dermatology providers in Oklahoma.

See all dermatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,473,964
Medicare patients
1,453
Services billed
15,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa15$307,828
Dupixent PenDupilumab59$247,902
OdomzoSonidegib Phosphate12$188,851
Dupixent SyringeDupilumab47$188,429
Humira(Cf) PenAdalimumab14$94,978
Taltz AutoinjectorIxekizumab12$81,329
Fluorouracil128$9,038
Clobetasol Propionate130$5,469
Ketoconazole249$4,712
Tacrolimus54$4,687
ZenataneIsotretinoin22$4,613
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc265$4,265
Dutasteride158$4,103
Triamcinolone Acetonide463$3,639
Acitretin12$3,491

Paid to pharmacies, not to this prescriber.

Other dermatology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →